PHVS

PHARVARIS N V

PHVS·N69605108·US·Common Stock·Healthcare - Biotechnology-13D/G

PHVS (PHARVARIS N V) is held by 57 institutional investors as of Q1 2026. Largest holders: FMR LLC ($177.5M), VIKING GLOBAL INVESTORS LP ($103.2M), WELLINGTON MANAGEMENT GROUP LLP ($59.9M). Net institutional sentiment: Mixed.

57
Holders
Avg rating(9 Elite)
$525.2M
Total Value
46% (60)
Fund Consensus
22 buying - 26 selling
PHVSSmart Money Verdict
View all
Held by 57 funds
9 elite
Who's Trading
InsiderNANijdam AnnaSell $82KJun 4, 2026
InsiderBEBjork ElisabethSell $293KMay 20, 2026
InsiderMBModig BerndtSell $67KMay 18, 2026
ActivistVIKING GLOBAL INVESTORS LPVIKING GLOBAL INVESTORS LP5.6%May 15, 2026
InsiderSWSouverijns WimSell $299KMay 15, 2026
InsiderGRGlassman RobertSell $159KMay 15, 2026
InsiderGRGlassman RobertSell $139KMay 15, 2026
InsiderLPLu PengExercise 14K shMay 1, 2026
InsiderLPLu PengSell $423KMay 1, 2026
ActivistBLBain Capital Life Sciences Fund, L.P.2.5%Feb 17, 2026
13F: Insider & Congress:
Fund
Action
Shares
Value
Weight
Est. P&L
Conviction
Decreased
6.3M(-1.8%)$177.5M0.0%+77.02%
0
Unchanged
3.7M$103.2M0.3%+52.52%
0
Increased
2.1M(+11.2%)$59.9M0.0%+42.14%
33
Increased
1M(+41.5%)$28.4M0.0%+39.84%
38
Increased
781,016(+228.2%)$22.1M0.1%+34.86%
46
Increased
757,213(+6.9%)$21.4M0.0%+47.47%
30
Decreased
462,251(-6.8%)$13.1M0.0%+44.56%
0
Decreased
442,256(-53.0%)$12.5M0.0%+55.87%
0
Unchanged
375,000$10.6M0.1%+44.56%
0
Increased
321,157(+23.3%)$9.1M0.0%+33.82%
33
Decreased
181,946(-26.9%)$5.1M0.0%+40.22%
0
Increased
168,630(+24.9%)$4.8M0.0%+48.83%
33
Decreased
164,323(-33.8%)$4.6M0.0%+45.81%
0
Decreased
152,945(-5.3%)$4.3M0.0%+64.99%
0
Unchanged
158,019$4.3M0.0%+34.38%
0
Decreased
142,929(-11.2%)$4M0.0%+34.52%
0
Decreased
126,076(-41.4%)$3.6M0.0%+34.10%
0
Unchanged
125,000$3.5M0.0%+44.56%
0
Decreased
96,384(-4.0%)$2.7M0.0%+33.60%
0
Increased
89,129(+2.7%)$2.5M0.0%+54.40%
27

Showing 1-20 of 60

1 / 3

Other Healthcare stocks held by institutions

Data sourced from four SEC data sources: 13F, Form 4, 13D/13G, and STOCK Act. Not financial advice. Full disclaimer

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used